Search

Your search keyword '"Spanholtz, Jan"' showing total 164 results
Start Over Author "Spanholtz, Jan" Publication Year Range Last 50 years
164 results on '"Spanholtz, Jan"'

8. Supplementary Figure 3 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Information from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 2 from Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., primary, Spanholtz, Jan, primary, Hangalapura, Basav N., primary, Tordoir, Marleen, primary, Maas, Frans, primary, Leenders, Marij, primary, Bohme, Fenna, primary, Kok, Nina, primary, Trilsbeek, Carel, primary, Paardekooper, Jos, primary, van der Waart, Anniek B., primary, Westerweel, Peter E., primary, Snijders, Tjeerd J.F., primary, Cornelissen, Jan, primary, Bos, Gerard, primary, Pruijt, Hans F.M., primary, de Graaf, Aniek O., primary, van der Reijden, Bert A., primary, Jansen, Joop H., primary, van der Meer, Arnold, primary, Huls, Gerwin, primary, Cany, Jeannette, primary, Preijers, Frank, primary, Blijlevens, Nicole M.A., primary, and Schaap, Nicolaas M., primary

Published
2023
Full Text
View/download PDF

12. Lipid nanoparticle-mediated messenger RNA delivery for ex vivo engineering of natural killer cells

Author

Afd Pharmaceutics, Pharmaceutics, Douka, Stefania, Brandenburg, Lisa E, Casadidio, Cristina, Walther, Johanna, Garcia, Bianca Bonetto Moreno, Spanholtz, Jan, Raimo, Monica, Hennink, Wim E, Mastrobattista, Enrico, Caiazzo, Massimiliano, Afd Pharmaceutics, Pharmaceutics, Douka, Stefania, Brandenburg, Lisa E, Casadidio, Cristina, Walther, Johanna, Garcia, Bianca Bonetto Moreno, Spanholtz, Jan, Raimo, Monica, Hennink, Wim E, Mastrobattista, Enrico, and Caiazzo, Massimiliano

Published
2023

13. 245 Cord blood CD34+stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ natural killer cells which display selective cytotoxicity against B-cell leukemia

Author

Raimo, Monica, primary, Lamers-Kok, Nina, additional, Özkazanc, Didem, additional, Steenmans, Daniëlle, additional, Shahini, Greis, additional, Vliet, Amanda van, additional, Panella, Denise, additional, Micciché, Arianna, additional, Waardenburg, Youri van, additional, Georgoudaki, Anna-Maria, additional, Spanholtz, Jan, additional, and Duru, Adil, additional

Published
2022
Full Text
View/download PDF

17. Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90

Author

Saha, Tanmoy, primary, van Vliet, Amanda A., additional, Cui, Chunxiao, additional, Macias, Jorge Jimenez, additional, Kulkarni, Arpita, additional, Pham, Luu Nhat, additional, Lawler, Sean, additional, Spanholtz, Jan, additional, Georgoudaki, Anna-Maria, additional, Duru, Adil Doganay, additional, and Goldman, Aaron, additional

Published
2021
Full Text
View/download PDF

18. Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor

Author

Toffoli, Elisa C., primary, Sheikhi, Abdolkarim, additional, Lameris, Roeland, additional, King, Lisa A., additional, van Vliet, Amanda, additional, Walcheck, Bruce, additional, Verheul, Henk M. W., additional, Spanholtz, Jan, additional, Tuynman, Jurriaan, additional, de Gruijl, Tanja D., additional, and van der Vliet, Hans J., additional

Published
2021
Full Text
View/download PDF

21. A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, ex vivo-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.

Author

Heuser, Michael, primary, Fiedler, Walter M., additional, Kerre, Tessa, additional, Maertens, Johan, additional, Passweg, Jakob, additional, Van De Loosdrecht, Arjan, additional, Mueller, Antonia Maria, additional, Bourhis, Jean-Henri, additional, Nowek, Katarzyna, additional, Spanholtz, Jan, additional, Bonnamain, Virginie, additional, Winckels, Stephan, additional, and Ganser, Arnold, additional

Published
2021
Full Text
View/download PDF

22. Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90

Author

Massachusetts Institute of Technology. Department of Chemistry, Saha, Tanmoy, van Vliet, Amanda A., Cui, Chunxiao, Macias, Jorge Jimenez, Kulkarni, Arpita, Pham, Luu Nhat, Lawler, Sean, Spanholtz, Jan, Georgoudaki, Anna-Maria, Duru, Adil Doganay, Goldman, Aaron, Massachusetts Institute of Technology. Department of Chemistry, Saha, Tanmoy, van Vliet, Amanda A., Cui, Chunxiao, Macias, Jorge Jimenez, Kulkarni, Arpita, Pham, Luu Nhat, Lawler, Sean, Spanholtz, Jan, Georgoudaki, Anna-Maria, Duru, Adil Doganay, and Goldman, Aaron

Abstract

Allogeneic natural killer (aNK) cell adoptive therapy has the potential to dramatically impact clinical outcomes of glioblastoma multiforme (GBM). However, in order to exert therapeutic activity, NK cells require tumor expression of ligands for activating receptors, such as MHC Class I peptide A/B (MICA/B) and ULBPs. Here, we describe the use of a blood–brain barrier (BBB) permissive supramolecular cationic drug vehicle comprising an inhibitor of the chaperone heat shock protein 90 (Hsp90), which sustains a cytotoxic effect on GBM cells, boosts the expression of MICA/B and ULBPs on the residual population, and augments the activity of clinical-grade aNK cells (GTA002). First, we identify Hsp90 mRNA transcription and gain of function as significantly upregulated in GBM compared to other central nervous system tumors. Through a rational chemical design, we optimize a radicicol supramolecular prodrug containing cationic excipients, SCI-101, which displays >2-fold increase in relative BBB penetration compared to less cationic formulations in organoids, in vitro. Using 2D and 3D biological models, we confirm SCI-101 sustains GBM cytotoxicity 72 h after drug removal and induces cell surface MICA/B protein and ULBP mRNA up to 200% in residual tumor cells compared to the naked drug alone without augmenting the shedding of MICA/B, in vitro. Finally, we generate and test the sequential administration of SCI-101 with a clinical aNK cell therapy, GTA002, differentiated and expanded from healthy umbilical cord blood CD34+ hematopoietic stem cells. Using a longitudinal in vitro model, we demonstrate >350% relative cell killing is achieved in SCI-101–treated cell lines compared to vehicle controls. In summary, these data provide a first-of-its-kind BBB-penetrating, long-acting inhibitor of Hsp90 with monotherapy efficacy, which improves response to aNK cells

Published
2021

26. The long COVID of energy markets and prices.

Author

Chenyan Lyu, Jamasb, Tooraj, and Spanholtz, Jan Peter Georg

Subjects
POST-acute COVID-19 syndrome, MARKET prices, MARKET pricing, ENERGY consumption, ENERGY shortages, NATURAL gas
Abstract

The 2021 energy crisis comes at an inconvenient time for the green transition agenda and can affect disposable income, unemployment and inflation. This article discusses the likely effects and implications for energy networks and policy. The economic principles behind the crisis may seem intractable, but they are familiar. A combination of known factors has caused the crisis. Europe is dependent on gas imports and a shortage of supplies has contributed to rising gas and electricity prices. The low-price elasticity of energy demand and supply makes them susceptible to price volatility even with modest quantity shocks. Higher CO2 abatement costs have forced some firms to increase their reliance on natural gas, which in turn drives up the gas prices. The crisis has brought forward the need for some overdue measures and policies including a more robust transition management, new transmission capacity, more storage, balance of contract types, and network regulation models. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

27. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer

Author

Veluchamy, John Pradeep and Spanholtz, Jan

Abstract

The ability of Natural Killer (NK) cells to kill tumor targets has been extensively studied in various hematological malignancies. However, NK cell therapy directed against solid tumors is still in early development. Epidermal Growth Factor Receptor (EGFR) targeted therapies using monoclonal antibodies (mAbs) such as cetuximab and panitumumab are widely used for the treatment of metastatic colorectal cancer (mCRC). Still, the clinical efficacy of this treatment is hampered by mutations in RAS gene, allowing tumors to escape from anti-EGFR mAb therapy. It is well established that NK cells kill tumor cells by natural cytotoxicity and can in addition be activated upon binding of IgG1 mAbs through Fc receptors (CD16/Fc?RIIIa) on their surface, thereby mediating antibody dependent cellular cytotoxicity (ADCC). In the current study, activated Peripheral Blood NK cells (PBNK) were combined with anti-EGFR mAbs to study their effect on the killing of EGFR+/- cancer cell lines, including those with RAS mutations. In vitrocytotoxicity experiments using colon cancer primary tumors and cell lines COLO320, Caco-2, SW620, SW480 and HT-29, demonstrated that PBNK cells are cytotoxic for a range of tumor cells, regardless of EGFR, RAS or BRAF status and at low E:T ratios. Cetuximab enhanced the cytotoxic activity of NK cells on EGFR+ tumor cells (either RASwt, RASmut or BRAFmut) in a CD16 dependent manner, whereas it could not increase the killing of EGFR- COLO320. Our study provides a rationale to strengthen NK cell immunotherapy through a combination with cetuximab for RAS and BRAF mutant mCRC patients.

Published
2016

28. Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., additional, Spanholtz, Jan, additional, Hangalapura, Basav N., additional, Tordoir, Marleen, additional, Maas, Frans, additional, Leenders, Marij, additional, Bohme, Fenna, additional, Kok, Nina, additional, Trilsbeek, Carel, additional, Paardekooper, Jos, additional, van der Waart, Anniek B., additional, Westerweel, Peter E., additional, Snijders, Tjeerd J.F., additional, Cornelissen, Jan, additional, Bos, Gerard, additional, Pruijt, Hans F.M., additional, de Graaf, Aniek O., additional, van der Reijden, Bert A., additional, Jansen, Joop H., additional, van der Meer, Arnold, additional, Huls, Gerwin, additional, Cany, Jeannette, additional, Preijers, Frank, additional, Blijlevens, Nicole M.A., additional, and Schaap, Nicolaas M., additional

Published
2017
Full Text
View/download PDF

30. The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell Development

Author

Post, Mirte, primary, Cuapio, Angelica, additional, Osl, Markus, additional, Lehmann, Dorit, additional, Resch, Ulrike, additional, Davies, David M., additional, Bilban, Martin, additional, Schlechta, Bernhard, additional, Eppel, Wolfgang, additional, Nathwani, Amit, additional, Stoiber, Dagmar, additional, Spanholtz, Jan, additional, Casanova, Emilio, additional, and Hofer, Erhard, additional

Published
2017
Full Text
View/download PDF

34. Wnt3a protein reduces growth factor-driven expansion of human hematopoietic stem and progenitor cells in serum-free cultures

Author

Duinhouwer, Lucia E., Tüysüz, Nesrin, Rombouts, Elwin W J C, Ter Borg, Mariette N D, Mastrobattista, Enrico, Spanholtz, Jan, Cornelissen, Jan J., Berge, Derk Ten, Braakman, Eric, Sub Drug delivery, UIPS - Utrecht Institute for Pharmaceutical Sciences, Pharmaceutics, Sub Drug delivery, UIPS - Utrecht Institute for Pharmaceutical Sciences, Pharmaceutics, Hematology, and Cell biology

Subjects
Cellular differentiation, medicine.medical_treatment, CD34, lcsh:Medicine, Antigens, CD34, Biology, Biochemistry, Culture Media, Serum-Free, Glycogen Synthase Kinase 3, Mice, Mice, Inbred NOD, Wnt3A Protein, medicine, Animals, Humans, Cell Lineage, Progenitor cell, lcsh:Science, Wnt Signaling Pathway, Cells, Cultured, beta Catenin, Medicine(all), Multidisciplinary, Agricultural and Biological Sciences(all), Biochemistry, Genetics and Molecular Biology(all), Growth factor, Stem Cells, lcsh:R, Wnt signaling pathway, Hematopoietic Stem Cell Transplantation, Cell Differentiation, Parkinson Disease, Fetal Blood, Hematopoietic Stem Cells, Cell biology, Haematopoiesis, Receptors, Aryl Hydrocarbon, Liposomes, lcsh:Q, Stem cell, Research Article, Genetics and Molecular Biology(all)
Abstract

Ex vivo expansion of hematopoietic stem and progenitor cells (HSPC) is a promising approach to improve insufficient engraftment after umbilical cord blood stem cell transplantation (UCB-SCT). Although culturing HSPC with hematopoietic cytokines results in robust proliferation, it is accompanied with extensive differentiation and loss of self-renewal capacity. Wnt signaling has been implicated in regulating HSPC fate decisions in vivo and in promoting HSPC self-renewal by inhibition of differentiation, but the effects of Wnt on the ex vivo expansion of HSPC are controversial. Here, we demonstrate that exogenous Wnt3a protein suppresses rather than promotes the expansion of UCB-derived CD34(+) cells in serum free expansion cultures. The reduced expansion was also observed in cultures initiated with Lin(-)CD34(+)CD38(low)CD45RA(-)CD90(+) cells which are highly enriched in HSC and was also observed in response to activation of beta-catenin signaling by GSK3 inhibition. The presence of Wnt3a protein during the culture reduced the frequency of multilineage CFU-GEMM and the long-term repopulation ability of the expanded HSPC. These data suggest that Wnt signaling reduces expansion of human HSPC in growth factor-driven expansion cultures by promoting differentiation of HSPC.

Published
2015

35. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status

Author

Veluchamy, John P., primary, Heeren, A. Marijne, additional, Spanholtz, Jan, additional, van Eendenburg, Jaap D. H., additional, Heideman, Daniëlle A. M., additional, Kenter, Gemma G., additional, Verheul, Henk M., additional, van der Vliet, Hans J., additional, Jordanova, Ekaterina S., additional, and de Gruijl, Tanja D., additional

Published
2016
Full Text
View/download PDF

37. Allogeneic NK cells generated from cord blood as universal treatment for cervical cancer enabled by HLA independent killing mechanisms.

Author

Veluchamy, John, primary, Heeren, A.Marijne, additional, Spanholtz, Jan, additional, van Eendenburg, Jaap D.H, additional, Heideman, Danielle, additional, Verheul, Henk M.W., additional, Kenter, Gemma, additional, Van Der Vliet, Hans J., additional, Jordanova, Ekaterina S., additional, and de Gruijl, Tanja D., additional

Published
2016
Full Text
View/download PDF

39. Wnt3a protein reduces growth factor-driven expansion of human hematopoietic stem and progenitor cells in serum-free cultures

Author

Sub Drug delivery, UIPS - Utrecht Institute for Pharmaceutical Sciences, Pharmaceutics, Duinhouwer, Lucia E., Tüysüz, Nesrin, Rombouts, Elwin W J C, Ter Borg, Mariette N D, Mastrobattista, Enrico, Spanholtz, Jan, Cornelissen, Jan J., Berge, Derk Ten, Braakman, Eric, Sub Drug delivery, UIPS - Utrecht Institute for Pharmaceutical Sciences, Pharmaceutics, Duinhouwer, Lucia E., Tüysüz, Nesrin, Rombouts, Elwin W J C, Ter Borg, Mariette N D, Mastrobattista, Enrico, Spanholtz, Jan, Cornelissen, Jan J., Berge, Derk Ten, and Braakman, Eric

Published
2015

40. A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients

Author

Dolstra, Harry, primary, Roeven, Mieke W.H., additional, Spanholtz, Jan, additional, Hangalapura, Basav, additional, Tordoir, Marleen, additional, Maas, Frans, additional, Leenders, Marij, additional, Bohme, Fenna, additional, Kok, Nina, additional, Trilsbeek, Carel, additional, Paardekooper, Jos, additional, Van der Waart, Anniek B., additional, Westerweel, Peter, additional, Snijders, Tjeerd J.F., additional, Bos, Gerard M.J., additional, Cornelissen, Jan J., additional, Pruijt, Hans, additional, Huls, Gerwin, additional, de Graaf, Aniek, additional, van der Reijden, Bert A., additional, Blijlevens, Nicole M.A., additional, Jansen, Joop H., additional, van der Meer, Arnold, additional, Cany, Jeannette, additional, Preijers, Frank, additional, and Schaap, Nicolaas P.M., additional

Published
2015
Full Text
View/download PDF

49. Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice

Author

Cany, Jeannette, primary, van der Waart, Anniek B., additional, Tordoir, Marleen, additional, Franssen, Gerben M., additional, Hangalapura, Basav N., additional, de Vries, Jolanda, additional, Boerman, Otto, additional, Schaap, Nicolaas, additional, van der Voort, Robbert, additional, Spanholtz, Jan, additional, and Dolstra, Harry, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results